This company listing is no longer active
Biodexa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Biodexa Pharmaceuticals has been growing earnings at an average annual rate of 4.3%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 14% per year.
Key information
4.3%
Earnings growth rate
61.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -14.0% |
| Return on equity | -71.6% |
| Net Margin | -832.1% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biodexa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 1 | -5 | 3 | 0 |
| 31 Mar 22 | 1 | -5 | 3 | 0 |
| 31 Dec 21 | 1 | -5 | 3 | 0 |
| 30 Sep 21 | 1 | -7 | 3 | 2 |
| 30 Jun 21 | 1 | -8 | 3 | 2 |
| 31 Mar 21 | 0 | -15 | 4 | 1 |
| 31 Dec 20 | 0 | -22 | 4 | 0 |
| 30 Jun 20 | 0 | -22 | 5 | 0 |
| 31 Mar 20 | 1 | -16 | 5 | 0 |
| 31 Dec 19 | 1 | -9 | 4 | 0 |
| 30 Jun 19 | 2 | -9 | 4 | 0 |
| 31 Mar 19 | 2 | -10 | 4 | 0 |
| 31 Dec 18 | 2 | -10 | 4 | 0 |
| 30 Jun 18 | 1 | -11 | 4 | 0 |
| 31 Mar 18 | 1 | -11 | 4 | 0 |
| 31 Dec 17 | 1 | -12 | 4 | 0 |
| 30 Sep 17 | -3 | -1 | -7 | -5 |
| 30 Jun 17 | 4 | -18 | 10 | 6 |
| 31 Mar 17 | 6 | -19 | 14 | 7 |
| 31 Dec 16 | 1 | -6 | 3 | 0 |
| 30 Sep 16 | 5 | -17 | 12 | 10 |
| 30 Jun 16 | 4 | -13 | 13 | 6 |
Quality Earnings: 5MP0 is currently unprofitable.
Growing Profit Margin: 5MP0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5MP0 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare 5MP0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5MP0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.2%).
Return on Equity
High ROE: 5MP0 has a negative Return on Equity (-71.65%), as it is currently unprofitable.